Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Synopsys, Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.11 (market cap $12.58B), while Synopsys, Inc. trades at $508.09 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 7.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Synopsys, Inc. is more actively traded (3,374,903 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Synopsys, Inc. for 71 Days on average.
| HALO | SNPS | |
|---|---|---|
Market Cap | $12.58B | $95.39B |
Volume | 2,179,278 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $115.22 | $534.56 |
52-Week Low | $61.63 | $367.70 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $14.49B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights AI-driven partnerships with OpenAI and Amazon, boosting growth prospects. Valuation ratios are elevated, with a P/E of 86.87, reflecting high growth expectations. Analyst sentiment is overwhelmingly positive, with a consensus price target of $572.54.
The outlook for SNPS is favorable, driven by AI integration and strategic acquisitions, but risks include high valuation sensitivity and competitive pressures. Revenue growth and margin expansion from new deals present opportunities, though investors should monitor execution risks and market volatility. The stock's proximity to key resistance levels suggests potential for near-term consolidation or breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
